ihc staining of brd4 Search Results


ihc staining of brd4  (Human Protein Atlas)
90
Human Protein Atlas ihc staining of brd4
JQ1 is a promising candidate in combination with ABE. A Ranked synergy models of ABE and screened epigenetic drugs, including JQ1, tazemetostat, vorinostat, 5-azacitidine, SETDB1-TTD-IN-1 and UNC669. Synergy scores were labelled to the top of each model. B Dependency score of CDK4 and <t>BRD4</t> for tumor cells across different cancer types. Score < 0 represents essential genes and Score < -1 represents super essential genes. C Transcriptional expression level of BRD4 between tumor and normal tissues in TCGA-STAD cohort. D Immunohistochemistry (IHC) staining of BRD4 in GC patients from The Human Protein Atlas. E CUT&Tag-seq binding enrichment of H3K27ac in AGS cells treated with DMSO or ABE. F Pie plot of the genomic distribution of H3K27ac peaks in ABE-treated AGS cells. G Gene tracks depicting H3K27ac signals at the BRD4 locus. The signal from ABE and DMSO was normalized at same level. H Western blotting images showing the protein level of BRD4 protein level after ABE treatment. GAPDH was used as a loading control. I Quantification of the protein level of BRD4 in AGS cells after ABE treatment for 24 h using ImageJ software. The data are presented as the mean ± SEM of three replicates. J Enrichment analysis of top1000 upregulated H3K27ac peaks in ABE-treated AGS cells. K Gene tracks depicting H3K27ac signals at the SMAD3, VCL, SNAI1 and RAC1 locus. The signals from ABE and DMSO were normalized at same level
Ihc Staining Of Brd4, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ihc staining of brd4/product/Human Protein Atlas
Average 90 stars, based on 1 article reviews
ihc staining of brd4 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


JQ1 is a promising candidate in combination with ABE. A Ranked synergy models of ABE and screened epigenetic drugs, including JQ1, tazemetostat, vorinostat, 5-azacitidine, SETDB1-TTD-IN-1 and UNC669. Synergy scores were labelled to the top of each model. B Dependency score of CDK4 and BRD4 for tumor cells across different cancer types. Score < 0 represents essential genes and Score < -1 represents super essential genes. C Transcriptional expression level of BRD4 between tumor and normal tissues in TCGA-STAD cohort. D Immunohistochemistry (IHC) staining of BRD4 in GC patients from The Human Protein Atlas. E CUT&Tag-seq binding enrichment of H3K27ac in AGS cells treated with DMSO or ABE. F Pie plot of the genomic distribution of H3K27ac peaks in ABE-treated AGS cells. G Gene tracks depicting H3K27ac signals at the BRD4 locus. The signal from ABE and DMSO was normalized at same level. H Western blotting images showing the protein level of BRD4 protein level after ABE treatment. GAPDH was used as a loading control. I Quantification of the protein level of BRD4 in AGS cells after ABE treatment for 24 h using ImageJ software. The data are presented as the mean ± SEM of three replicates. J Enrichment analysis of top1000 upregulated H3K27ac peaks in ABE-treated AGS cells. K Gene tracks depicting H3K27ac signals at the SMAD3, VCL, SNAI1 and RAC1 locus. The signals from ABE and DMSO were normalized at same level

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma

doi: 10.1186/s13046-023-02615-2

Figure Lengend Snippet: JQ1 is a promising candidate in combination with ABE. A Ranked synergy models of ABE and screened epigenetic drugs, including JQ1, tazemetostat, vorinostat, 5-azacitidine, SETDB1-TTD-IN-1 and UNC669. Synergy scores were labelled to the top of each model. B Dependency score of CDK4 and BRD4 for tumor cells across different cancer types. Score < 0 represents essential genes and Score < -1 represents super essential genes. C Transcriptional expression level of BRD4 between tumor and normal tissues in TCGA-STAD cohort. D Immunohistochemistry (IHC) staining of BRD4 in GC patients from The Human Protein Atlas. E CUT&Tag-seq binding enrichment of H3K27ac in AGS cells treated with DMSO or ABE. F Pie plot of the genomic distribution of H3K27ac peaks in ABE-treated AGS cells. G Gene tracks depicting H3K27ac signals at the BRD4 locus. The signal from ABE and DMSO was normalized at same level. H Western blotting images showing the protein level of BRD4 protein level after ABE treatment. GAPDH was used as a loading control. I Quantification of the protein level of BRD4 in AGS cells after ABE treatment for 24 h using ImageJ software. The data are presented as the mean ± SEM of three replicates. J Enrichment analysis of top1000 upregulated H3K27ac peaks in ABE-treated AGS cells. K Gene tracks depicting H3K27ac signals at the SMAD3, VCL, SNAI1 and RAC1 locus. The signals from ABE and DMSO were normalized at same level

Article Snippet: D Immunohistochemistry (IHC) staining of BRD4 in GC patients from The Human Protein Atlas.

Techniques: Expressing, Immunohistochemistry, Binding Assay, Western Blot, Control, Software

CDK4/6 and BRD4 Inhibition Specifically induce cell senescence and DNA damage in vitro. A , C , E Immunofluorescence staining of the DNA damage marker γH2AX (scale bar = 25 μm), DNA senescence marker p21 and p53 (scale bar = 50 μm ) in AGS cell line upon the treatment of the indicted agents for 24 h. B , D , F Quantification of the positive cell ratio and mean fluorescence intensity using QuPath software. The data are presented as the mean ± SEM of three replicates. G Western blotting images showing the protein level of Phospho-Rb (Ser807/811), γH2AX, p53 and p21 in AGS cells from the indicted treatment cohort. GAPDH was used as a loading control. H Quantification of the protein level of Phospho-Rb (Ser807/811), γH2AX, p53 and p21 in AGS cells from the indicted treatment for 24 h using imageJ software. The data are presented as the mean ± SEM of three replicates. Significance of each group was compared with DMSO group

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma

doi: 10.1186/s13046-023-02615-2

Figure Lengend Snippet: CDK4/6 and BRD4 Inhibition Specifically induce cell senescence and DNA damage in vitro. A , C , E Immunofluorescence staining of the DNA damage marker γH2AX (scale bar = 25 μm), DNA senescence marker p21 and p53 (scale bar = 50 μm ) in AGS cell line upon the treatment of the indicted agents for 24 h. B , D , F Quantification of the positive cell ratio and mean fluorescence intensity using QuPath software. The data are presented as the mean ± SEM of three replicates. G Western blotting images showing the protein level of Phospho-Rb (Ser807/811), γH2AX, p53 and p21 in AGS cells from the indicted treatment cohort. GAPDH was used as a loading control. H Quantification of the protein level of Phospho-Rb (Ser807/811), γH2AX, p53 and p21 in AGS cells from the indicted treatment for 24 h using imageJ software. The data are presented as the mean ± SEM of three replicates. Significance of each group was compared with DMSO group

Article Snippet: D Immunohistochemistry (IHC) staining of BRD4 in GC patients from The Human Protein Atlas.

Techniques: Inhibition, In Vitro, Immunofluorescence, Staining, Marker, Fluorescence, Software, Western Blot, Control